Company profile: Abcuro
1.1 - Company Overview
Company description
- Provider of immunotherapies for autoimmunity and cancer, including ABC008, a monoclonal antibody targeting KLRG1 to selectively deplete highly cytotoxic T cells in inclusion body myositis, T-cell large granular lymphocytic leukemia, and certain cancers, and ABC015, a preclinical antibody blocking KLRG1-ligand interaction to activate cytotoxic T and NK cells; conducts clinical trials for ABC008 in IBM and T-LGLL.
Products and services
- ABC008: A clinical-stage monoclonal antibody targeting KLRG1 to selectively deplete highly cytotoxic T cells in inclusion body myositis, T-LGLL, and certain cancers
- Clinical Trials for ABC008: A multi-indication program evaluating safety, tolerability, and efficacy of ABC008 in inclusion body myositis and T-cell large granular lymphocytic leukemia
- ABC015: A preclinical monoclonal antibody engineered to block KLRG1–ligand interactions on cancer cells, activating cytotoxic T and NK cells to promote anti-tumor activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Abcuro
Alzamend Neuro
HQ: United States
Website
- Description: Provider of biotech therapies for Alzheimer's disease that develops and commercializes drugs, treatments, and cures. Includes AL001, an ionic cocrystal delivering lithium via lithium/proline/salicylate for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD; and ALZN002, a cell-based therapeutic vaccine using a mutant-peptide sensitized cell to restore the patient's immune system's ability to combat Alzheimer's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alzamend Neuro company profile →
NovAccess Global
HQ: United States
Website
- Description: Provider of cancer and neurological disease immunotherapies and diagnostics, combining clinical-stage asset acquisition with medical assets in the market. Through StemVax Therapeutics, develops dendritic cell-based immunotherapies for glioblastoma with TLR adjuvants, and leverages AI, bio-sensing, and blockchain-powered AI to advance diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NovAccess Global company profile →
Jennerex
HQ: United States
Website
- Description: Provider of targeted oncolytic products for cancer, focused on development and commercialization of first-in-class therapies. Lead candidate Pexa-Vec (JX-594), a targeted oncolytic virus that selectively infects and destroys cancer cells, is in international Phase 2 trials for primary liver and colorectal cancers after promising Phase 1 efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jennerex company profile →
Circassia
HQ: United Kingdom
Website
- Description: Provider of point-of-care asthma diagnostics and management solutions, including NIOX VERO and FeNO by NIOX for measuring fractional exhaled nitric oxide to assess airway inflammation, used by physicians worldwide to aid diagnosis and management, with dedicated customer service and after-sales support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Circassia company profile →
Apexigen
HQ: United States
Website
- Description: Provider of clinical-stage immuno-oncology antibody therapeutics for cancer, including sotigalimab (PYX-107), a Phase 2 CD40 agonist with demonstrated anti-cancer activity in patients who have progressed on PD-(L)1 inhibitors, and the APXiMAB platform for generating novel antibodies optimized for targeted payload delivery in antibody-drug conjugates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apexigen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Abcuro
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Abcuro
2.2 - Growth funds investing in similar companies to Abcuro
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Abcuro
4.2 - Public trading comparable groups for Abcuro
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →